Want to join the conversation?
$FTR 2Q15 Q&A: Levi of UBS asked about stability trends for consumer and business in 3Q15. Daniel replied that FTR is continuing to see the same trends as in 2Q15 and continues to see opportunities on the commercial side to potentially grow similar to 2Q15.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.